Sup­ply con­straints push EpiPen ri­val mak­er Am­neal to re­struc­ture, shares fall

Am­neal Phar­ma­ceu­ti­cals, which sells a gener­ic ep­i­neph­rine au­to-in­jec­tor sim­i­lar to My­lan’s flag­ship Epipen, has ini­ti­at­ed a sweep­ing re­struc­tur­ing of its busi­ness dri­ven pri­mar­i­ly by the un­cer­tain­ty sur­round­ing the sup­ply of the emer­gency shot.

The Bridge­wa­ter, New Jer­sey-based com­pa­ny — which de­vel­ops and sells a raft of gener­ic, brand and biosim­i­lar prod­ucts — last year in May swal­lowed Im­pax Lab­o­ra­to­ries gain­ing ac­cess to its life-sav­ing al­ler­gy shot Adrenaclick. Days lat­er, the FDA said the prod­uct, along with My­lan’s $MYL EpiPen, were ex­pe­ri­enc­ing short­ages. As of June 2019, My­lan and Am­neal con­tin­ue to face sup­ply con­straints, ac­cord­ing to the health reg­u­la­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.